Andrew Haydon

Adj Assoc Prof


Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output


Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?

Segelov, E., Blinman, P., Martin, A., Goldstein, D., Cronk, M., Boadle, D., Tebbutt, N., Paul, J. & Haydon, A., 2018.

Research output: Contribution to conferenceAbstract


The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.

Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Mann, K., Elez, M. E., Chantrill, L. A., Pavlakis, N., Nott, L., Underhill, C., Khasraw, M., Wasan, H., Ciardiello, F., Jefford, M. J., Joubert, W., Haydon, A. M. M., Karapetis, C., Price, T. J., Wilson, K. & Shapiro, J., 2015, p. S726. 1 p.

Research output: Contribution to conferenceAbstract